Hydroxyurea: Clinical Trials

15 trials of Hydroxyurea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 15 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable15Completed 12, Active not recruiting 1, Recruiting 1, Unknown 1

Follow Hydroxyurea: new trials by email Literature Review of Hydroxyurea trials Research Report on Hydroxyurea

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia
Thalidomide, Hydroxy Urea - Thalassemia
Not applicableRecruitingRiphah International University2402026-06-202026-08-06
Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community
Hydroxyurea - Sickle Cell Disease, Stroke
Not applicableUnknownBarau Dikko Teaching Hospital2172021-01-062023-08-01
Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
Hydroxyurea - Sickle-Cell Anaemia
Not applicableCompletedUniversity of Kinshasa1662017-08-302023-01-12
Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya
Zinc Sulfate Tablets, Standard of Care - Sickle Cell Disease, Zinc Deficiency
Not applicableCompletedLucas Otieno Tina, MD MSc402016-05-202017-09-26
SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia
Hydroxyurea, TCD examination - Sickle Cell Anemia
Not applicableCompletedChildren's Hospital Medical Center, Cincinnati2832016-03-162025-08-22
Therapeutic Response Evaluation and Adherence Trial (TREAT)
Hydroxyurea - Anemia, Sickle Cell
Not applicableActive not recruitingChildren's Hospital Medical Center, Cincinnati1502014-10-012025-07-17
Sickle Cell Disease - Stroke Prevention in Nigeria Trial
Hydroxyurea - Sickle Cell Anemia, Sickle Cell Disease
Not applicableCompletedVanderbilt University Medical Center292013-04-242020-08-03
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major
Hydroxyurea - Beta-Thalassemia
Not applicableCompletedUniversity of Washington262006-07-012012-12-20
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
Tenofovir, Hydroxyurea - HIV Infections, AIDS
Not applicableCompletedUniversity of Maryland, Baltimore92003-06-012021-05-11
Hydroxyurea in Young Children With Sickle Cell Anemia
hydroxyurea - Sickle Cell Anemia
Not applicableCompletedDuke University142002-04-012007-08-23
Primary Thrombocythaemia 1 Trial
Hydroxyurea, Aspirin - Thrombocythemia, Myeloproliferative Disorder
Not applicableCompletedUniversity of Cambridge13981997-07-012017-01-18
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
Hydroxyurea, Nelfinavir mesylate, Stavudine - HIV Infections
Not applicableCompletedBristol-Myers Squibb1997-05-012011-04-14
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
Hydroxyurea, Nelfinavir mesylate, Stavudine - HIV Infections
Not applicableCompletedBristol-Myers Squibb1997-05-012011-04-14
Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
clotrimazole, hydroxyurea - Sickle Cell Anemia
Not applicableCompletedBoston Children's Hospital201997-04-012015-03-25
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir - HIV Infections
Not applicableCompletedNational Institute of Allergy and Infectious Diseases (NIAID)9002012-06-07

Conditions studied

Anemia, Sickle Cell (8)  ·  HIV Infections (4)  ·  Stroke (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Genetic Diseases, Inborn (1)  ·  Hematologic Diseases (1)  ·  Hemorrhage (1)  ·  Infections (1)  ·  Myeloproliferative Disorders (1)  ·  Rare Diseases (1)  ·  Thalassemia (1)  ·  Thrombocytosis (1)  ·  Thrombosis (1)  ·  beta-Thalassemia (1)

Sponsors

Bristol-Myers Squibb (2)  ·  Children's Hospital Medical Center, Cincinnati (2)  ·  Barau Dikko Teaching Hospital (1)  ·  Boston Children's Hospital (1)  ·  Duke University (1)  ·  Lucas Otieno Tina, MD MSc (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Riphah International University (1)  ·  University of Cambridge (1)  ·  University of Kinshasa (1)  ·  University of Maryland, Baltimore (1)  ·  University of Washington (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (7)  ·  Nigeria (2)  ·  Democratic Republic of the Congo (1)  ·  Dominican Republic (1)  ·  Greece (1)  ·  Italy (1)  ·  Pakistan (1)  ·  Puerto Rico (1)  ·  United Kingdom (1)

Top investigators

Anthony R Green, Prof (1)  ·  Carlo Brugnara (1)  ·  Charles Quinn, MD, MS (1)  ·  Claire Harrison, Dr (1)  ·  Courtney D Thornburg, MD mS (1)  ·  Fariha Sardar, MBBS, FCPS (1)  ·  George Stamatoyannopoulos, MD, DrSci (1)  ·  Gregory Robbins (1)  ·  Halima Bello-Manga, MBBS,MPH (1)  ·  Lori Jordan, MD, PhD (1)  ·  Lucas O Tina, MD MSc (1)  ·  Michael R. DeBaun, MD, MPH (1)  ·  Muktar Aliyu, MBBS, MPH, DrPH (1)  ·  Prosper Lukusa Tshilobo (1)  ·  Robert R. Redfield, MD (1)

Results publications

PMID 14668455, PMID 14668456, PMID 15187476, PMID 16048984, PMID 16103764, PMID 16267764, PMID 16810109, PMID 17662759, PMID 20467286, PMID 24326304, PMID 26615061, PMID 28576754, PMID 30153096, PMID 31106898, PMID 33901188, PMID 34020272, PMID 34227124, PMID 37461538, PMID 38225633, PMID 39820633, PMID 41026975, PMID 42448315, PMID 42577886

NIH funding

R01NS094041 (1), R21NS080639 (1), U01HL066947 (1)